Sorry, the best answer is D. The most likely integrase mutations in a patient on raltegravir (which has a low genetic barrier to resistance) are Q148, N155 and Y143. These are often paired with additional secondary mutations that can occur in one of three pathways: Q148H with G140S, N155 with E92Q, and Y143R and T97A.
M184V confers resistance to emtricitabine and lamivudine, but its presence also increases susceptibility to tenofovir alafenamide, tenofovir disoproxil fumarate, and zidovudine. The K103N reverse transcriptase mutation is the most common NNRTI mutation. K65R is a mutation that develops in patients who are taking suboptimal antiretroviral therapy (i.e. regimens that do not completely suppress HIV RNA levels) and are on tenofovir alafenamide, tenofovir disoproxil fumarate, and/or abacavir. I47V and V32I are protease mutations that confer high-level resistance to some of the protease inhibitors. Integrated care incorporates HIV and medical management, psychiatric care, psychosocial support including case management, and substance use treatment while considering patients’ culture and intersectionality, paying special attention to LGBT individuals.